Advances in the production and downstream processing of antibodies

New Biotechnology

Volumn 28, Issue 5, 2011, Pages 458-463

  Chon, John H ^a   Zarbis Papastoitsis, Gregory ^b  

^a Percivia LLC   (United States)

^b Protein Production and Analytical Development Eleven Biotherapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; CELL LINES; CLINICAL DEVELOPMENT; DOWNSTREAM-PROCESSING; IN-PHASE; MONOCLONAL ANTIBODIES (MABS); PLATFORM TECHNOLOGY; PRE-CLINICAL; PURIFICATION PROCESS; REGULATORY REQUIREMENTS; STRUCTURAL SIMILARITY;

CELL CULTURE; DISEASES; MONOCLONAL ANTIBODIES; SURFACE PLASMON RESONANCE;

MANUFACTURE;

MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; BIOREACTOR; CANCER THERAPY; CHO CELL; DRUG PURIFICATION; GLYCOSYLATION; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL CULTURE TECHNIQUES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC TECHNIQUES;

ANIMALIA;

EID: 80052788049     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2011.03.015     Document Type: Review

References (94)

1. Birch J.R., Racher A.J. Antibody production. Adv. Drug Deliv. Rev. 2006, 58:671-685.
2. Morrow K.J. Advances in antibody manufacturing using mammalian cells. Biotechnol. Annu. Rev. 2007, 13:95-113.
3. Rodrigues M.E., et al. Technological progresses in monoclonal antibody production systems. Biotechnol. Prog. 2010, 26:332-351.
4. Kipriyanov S.M., Le Gall F. Generation and production of engineered antibodies. Mol. Biotechnol. 2004, 24:39-60.
5. Siegel D.L. Recombinant monoclonal antibody technology. Transfus. Clin. Biol. 2002, 9:15-22.
6. Scheller R.H. Why Cabilly must stand. Nat. Biotechnol. 2007, 25:1088-1089.
7. Waltz E. Industry waits for fallout from Cabilly. Nat. Biotechnol. 2007, 25:699-700.
8. Waltz E. Cabilly patent finale. Nat. Biotechnol. 2008, 26:846.
9. Waltz E. Four rebuffs for Cabilly. Nat. Biotechnol. 2008, 26:362.
10. Waltz E. Genentech's Cabilly victory. Nat. Biotechnol. 2009, 27:307.
11. Arbabi-Ghahroudi M., et al. Isolation of monoclonal antibody fragments from phage display libraries. Methods Mol. Biol. 2009, 502:341-364.
12. Vaswani S.K., Hamilton R.G. Humanized antibodies as potential therapeutic drugs. Ann. Allergy Asthma Immunol. 1998, 81:105-115.
13. Maggon K. Monoclonal antibody " gold rush" Curr. Med. Chem. 2007, 14:1978-1987.
14. Houdebine L.M. Antibody manufacture in transgenic animals and comparisons with other systems. Curr. Opin. Biotechnol. 2002, 13:625-629.
15. Kozlowski S., Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv. Drug Deliv. Rev. 2006, 58:707-722.
16. Morrow KJ. Antibody World Summit 2007 - SRI's Sixth Annual Meeting. Discovery & development/manufacturing & processing. 16-17 July 2007, New Brunswick, NJ, USA. IDrugs 2007;10:686-9.
17. Carton J.M., et al. Codon engineering for improved antibody expression in mammalian cells. Protein Expr. Purif. 2007, 55:279-286.
18. Chon J.H. Expression of Recombinant Proteins Using the PER.C6 Human Cells 2010, The BioProcessing Summit, Boston, MA.
19. Fang J., et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 2005, 23:584-590.
20. Hartman T.E., et al. Derivation and characterization of cholesterol-independent non-GS NS0 cell lines for production of recombinant antibodies. Biotechnol. Bioeng. 2007, 96:294-306.
21. Jones D., et al. High-level expression of recombinant IgG in the human cell line Per.C6. Biotechnol. Prog. 2003, 19:163-168.
22. Lim Y., et al. Engineering mammalian cells in bioprocessing - current achievements and future perspectives. Biotechnol. Appl. Biochem. 2010, 55:175-189.
23. Lindgren K., et al. Automation of cell line development. Cytotechnology 2009, 59:1-10.
24. Omasa T., et al. Cell engineering and cultivation of Chinese hamster ovary (CHO) cells. Curr. Pharm. Biotechnol. 2010, 11:233-240.
25. Ye J., et al. High-level protein expression in scalable CHO transient transfection. Biotechnol. Bioeng. 2009, 103:542-551.
26. Yoo E.M., et al. Myeloma expression systems. J. Immunol. Methods 2002, 261:1-20.
27. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009, 1:443-452.
28. Farid S.S. Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 848:8-18.
29. Li F., et al. Cell culture processes for monoclonal antibody production. MAbs 2010, 2:466-479.
30. Chiba Y., Jigami Y. Production of humanized glycoproteins in bacteria and yeasts. Curr. Opin. Chem. Biol. 2007, 11:670-676.
31. Gasser B., Mattanovich D. Antibody production with yeasts and filamentous fungi: on the road to large scale?. Biotechnol. Lett. 2007, 29:201-212.
32. Graumann K., Premstaller A. Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol. J. 2006, 1:164-186.
33. Ko K., et al. Production of antibodies in plants: approaches and perspectives. Curr. Top. Microbiol. Immunol. 2009, 332:55-78.
34. Komarova T.V., et al. Transient expression systems for plant-derived biopharmaceuticals. Expert Rev. Vaccines 2010, 9:859-876.
35. Nolke G., et al. Production of therapeutic antibodies in plants. Expert Opin. Biol. Ther. 2003, 3:1153-1162.
36. Olivier S., et al. EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity. MAbs 2010, 2:405-415.
37. Orzaez D., et al. Manufacturing antibodies in the plant cell. Biotechnol. J. 2009, 4:1712-1724.
38. Weidner M., et al. Expression of recombinant proteins in the methylotrophic yeast Pichia pastoris. J. Vis. Exp. 2010, 25.
39. Werner R.G., et al. Appropriate mammalian expression systems for biopharmaceuticals. Arzneimittelforschung 1998, 48:870-880.
40. Chhatre S., et al. The integrated simulation and assessment of the impacts of process change in biotherapeutic antibody production. Biotechnol. Prog. 2006, 22:1612-1620.
41. Imai-Nishiya H., et al. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol. 2007, 7:84.
42. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 2005, 21:11-16.
43. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci. 2009, 30:356-362.
44. Rita Costa A., et al. Guidelines to cell engineering for monoclonal antibody production. Eur. J. Pharm. Biopharm. 2009, 74:127-138.
45. Sanz L., et al. Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol. Sin. 2005, 26:641-648.
46. Tangri S., et al. Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr. Med. Chem. 2002, 9:2191-2199.
47. Trexler-Schmidt M., et al. Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing. Biotechnol. Bioeng. 2010, 106:452-461.
48. Werner R.G., et al. Glycosylation of therapeutic proteins in different production systems. Acta Paediatr. Suppl. 2007, 96:17-22.
49. Yamane-Ohnuki N., Satoh M. Production of therapeutic antibodies with controlled fucosylation. MAbs 2009, 1:230-236.
50. Fan L., et al. A high-yielding, generic fed-batch process for recombinant antibody production of GS-engineered cell lines. J. Microbiol. Biotechnol. 2009, 19:1695-1702.
51. DePalma A. Enhancement of Cell Culture Techniques 2009, Genetic Engineering and Biotechnology News, New Rochelle, NY.
52. DePalma A. Demand Increases for Specialized Media 2010, Genetic Engineering and Biotechnology News, New Rochelle, NY.
53. Burky J.E., et al. Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies. Biotechnol. Bioeng. 2007, 96:281-293.
54. Huang Y.M., et al. Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol. Prog. 2010, 26:1400-1410.
55. Shukla A.A., Thommes J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010, 28:253-261.
56. Steinmeyer D.E., McCormick E.L. The art of antibody process development. Drug Discov. Today 2008, 13:613-618.
57. Zhang J., et al. A novel function for selenium in biological system: selenite as a highly effective iron carrier for Chinese hamster ovary cell growth and monoclonal antibody production. Biotechnol. Bioeng. 2006, 95:1188-1197.
58. Abu-Absi S.F., et al. Defining process design space for monoclonal antibody cell culture. Biotechnol. Bioeng. 2010, 106:894-905.
59. Adamson L., et al. Development of a technology platform for large-scale clinical grade production of DC. Cytotherapy 2004, 6:363-371.
60. Del Val I.J., et al. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns. Biotechnol. Prog. 2010, 26:1505-1527.
61. Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol. J. 2008, 3:90-97.
62. Gottschalk U. Bioseparation in antibody manufacturing: the good, the bad and the ugly. Biotechnol. Prog. 2008, 24:496-503.
63. Jain E., Kumar A. Upstream processes in antibody production: evaluation of critical parameters. Biotechnol. Adv. 2008, 26:46-72.
64. Kelley B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol. Prog. 2007, 23:995-1008.
65. Mao L.N., et al. Downstream antibody purification using aqueous two-phase extraction. Biotechnol. Prog. 2010, 26:1662-1670.
66. Porter A.J., et al. Strategies for selecting recombinant CHO cell lines for cGMP manufacturing: realizing the potential in bioreactors. Biotechnol. Prog. 2010, 26:1446-1454.
67. Laffly E., Sodoyer R. Monoclonal antibodies, 30 years of success. J. Soc. Biol. 2006, 200:325-343.
68. Yang J.D., et al. Achievement of high cell density and high antibody productivity by a controlled-fed perfusion bioreactor process. Biotechnol. Bioeng. 2000, 69:74-82.
69. Dalm C. Acoustic Perfusion Processes for Hybridoma Cultures: Viability, Cell Cycle and Metabolic Analysis, Process Engineering Group 2007, Wageningen Universiteit, Wageningen, NL, p. 160.
70. Dalm M.C., et al. Effect of feed and bleed rate on hybridoma cells in an acoustic perfusion bioreactor: metabolic analysis. Biotechnol. Prog. 2007, 23:560-569.
71. Dalm M.C., et al. Effect of feed and bleed rate on hybridoma cells in an acoustic perfusion bioreactor: part I. Cell density, viability, and cell-cycle distribution. Biotechnol. Bioeng. 2004, 88:547-557.
72. Dalm M.C., et al. Stable hybridoma cultivation in a pilot-scale acoustic perfusion system: long-term process performance and effect of recirculation rate. Biotechnol. Bioeng. 2005, 91:894-900.
73. Schirmer E.B., et al. Primary clarification of very high-density cell culture harvests by enhanced cell settling. BioProcess Int. 2010, 8:32-39.
74. Carson K.L. Flexibility - the guiding principle for antibody manufacturing. Nat. Biotechnol. 2005, 23:1054-1058.
75. Sinclair A., Monge M. Biomanufacturing for the 21st century. BioProcess Int. 2004, 2:26-31.
76. Sinclair A., Monge M. Concept facility based on single-use systems, part 2. BioProcess Int. 2005, 3:51-55.
77. Wan M. Process Mapping: A Necessary Step in Product Lifecycle 2004, BioProcess Int Conf Excib, Boston, MA.
78. Aranakumari A., et al. Improved downstream process design for human monoclonal antibody production. BioPharm Int. 2007, 20:36-40.
79. Coco-Martin J.M., Harmsen M.M. A review of therapeutic protein expression by mammalian cells. BioProcess Int. 2008, 6:28-33.
80. Kelley B. Designing a 10 ton antibody process: is conventional chromatography limiting?. 232nd American Chemical Society Meeting: BIOT Division 2006.
81. Sinclair A. Maximizing the Economic Benefit of Disposables in Facilities 2006, Disposables for Biopharmaceutical Manufacturing, Dublin, Ireland.
82. Lim A.C.J., et al. Economic benefits of single-use membrane chromatography in polishing: a cost of goods model. BioProcess Int. 2007, 5:48-56.
83. Fahrner R.L., et al. Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol. Genet. Eng. Rev. 2001, 18:301-327.
84. Lain B., et al. Development of a high-capacity MAb capture step based on cation exchange chromatography. BioProcess Int. 2009, 7:26-34.
85. Jackewitz A. Reducing elution volumes with high capacity and improved mass transfer ion-exchange resins. BioProcess Int. 2008, 6:108-110.
86. Gagnon P. How to choose an industrial cation exchanger for IgG purification. BioProcess Int. 2010, 8:22-34.
87. Kuczewski M., et al. PEG precipitation: a powerful tool for monoclonal antibody purification. BioPharm Int. Suppl. 2010, March 2:11-18.
88. Noyes A., et al. Polyethylene glycol-enhanced binding of recombinant proteins in isocratice AEX. IBC Antibody Development and Production Conference 2009.
89. Hjorth R. Expanded-bed adsorption in industrial bioprocessing: recent developments. Trends Biotechnol. 1997, 15:230-235.
90. Douwenga R. Moving to the Next Level of Manufacturing 2009, BioProcess Intl, Raleigh, NC.
91. Kuczewski M., et al. A Single-use Purification Platform for Monoclonal Antibodies 2010, IBC Single-use Applications for Biopharmaceutical Manufacturing, La Jolla, CA.
92. Zhou J., Tressel T. Concepts in Q membrane chromatography for large scale antibody production. Biotechnol. Prog. 2006, 22:341-349.
93. Fraud N., et al. Hydrophobic membrane adsorbers for large-scale downstream processing. BioPharm Int. 2009, October:24-27.
94. Kuczewski M., et al. Development of a polishing step using a hydrophobic interaction membrane adsorber with a PER.C6-derived recombinant antibody. Biotechnol. Bioeng. 2010, 105:296-305.